SCHEMBL2855628

SCHEMBL2855628

FC(F)(F)Oc1ccc2nc(C(F)(F)F)cc(Cl)c2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NT5E P21589 4/20 0.60
▸ IGF1R P08069 5/20 0.46
▸ DHODH Q02127 2/20 0.46
▸ NPC1 O15118 2/20 0.43
▸ RAB9A P51151 2/20 0.43
▸ SCN5A Q14524 2/20 0.43
▸ GMNN O75496 1/20 0.43
▸ USP2 O75604 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ ADORA3 P0DMS8 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ PKM P14618 1/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ NFKB1 P19838 1/20 0.43
▸ SLC6A2 P23975 1/20 0.43
▸ SCN4A P35499 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14690602 0.86 DHODH (0.47) NT5EIGF1RDHODHNPC1RAB9A
SCHEMBL2709780 0.84 NT5E (0.60) NT5EIGF1RUSP2LMNATP53
SCHEMBL2854016 0.83 IGF1R (0.48) NT5EIGF1RDHODHNPC1RAB9A
SCHEMBL19149164 0.81 IGF1R (0.44) NT5EIGF1RDHODHNPC1RAB9A
SCHEMBL16832212 0.80 DHODH (0.56) NT5EIGF1RDHODHLMNATP53
SCHEMBL2709700 0.78 NT5E (0.70) NT5EIGF1RDHODHNPC1RAB9A
SCHEMBL30492143 0.78 NT5E (0.70) NT5EIGF1RDHODHNPC1RAB9A
SCHEMBL2709353 0.77 NT5E (0.68) NT5EIGF1RDHODHLMNASCN4A
SCHEMBL1536339 0.77 NT5E (0.70) NT5EIGF1RDHODHRAB9ALMNA
SCHEMBL31327779 0.77 NT5E (0.68) NT5EIGF1RDHODHLMNASCN4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790725-B2 Thiazolidine derivatives and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-07 — — US disclosed
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORPORATION (JP) 2007-11-08 — — US disclosed
US-20040259883-A1 Thiazolidine derivative and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-12-23 — — US disclosed
EP-1426366-A1 THIAZOLIDINE DERIVATIVE AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2004-06-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF DPP4, DPP7, DPP3 NT5E 1375/4885IGF1R 919/4885DHODH 1163/4885
US-20040259883-A1 Thiazolidine derivative and medicinal use thereof DPP4, DPP7, DPP3 NT5E 1896/4885IGF1R 328/4885DHODH 1123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback